## EMN: Eastman Chemical Company - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_20 2.1% below STRENGTH zone (4.0-10.0%); PEG 3.79 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($61.79)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. These 4 Measures Indicate That Eastman Chemical (NYSE:EMN) Is Using Debt Extensively**
- Source: Simply Wall Street | 20260105T130803 | Somewhat-Bearish | Relevance: 100%
- Eastman Chemical (NYSE:EMN) makes extensive use of debt, with net debt around US$4.73 billion. While its EBIT covers interest expenses, its liabilities, totaling US$7.37 billion more than its cash and near-term receivables, exceed its US$7.34 billion market capitalization, suggesting potential risk. The company's free cash flow conversion of 45% of EBIT is weaker than expected, making debt management more challenging.

**2. These 4 Measures Indicate That Eastman Chemical (NYSE:EMN) Is Using Debt Extensively**
- Source: Simply Wall Street | 20260105T132512 | Somewhat-Bearish | Relevance: 100%
- Eastman Chemical Company (NYSE:EMN) utilizes debt, holding US$5.21b in debt against US$489.0m in cash, resulting in net debt of approximately US$4.73b as of September 2025. The company's liabilities of US$7.37b also exceed its US$7.34b market capitalization. Despite its interest expense being covered 5.7 times by EBIT, a cautious outlook is warranted due to less-than-expected free cash flow generation and liabilities outpacing assets.

**3. Eastman Chemical Company (NYSE:EMN) Given Consensus Rating of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20260104T070757 | Neutral | Relevance: 100%
- Fourteen brokerages have given Eastman Chemical Company (NYSE:EMN) a consensus "Moderate Buy" rating, with an average 12-month price target of $78.77. Despite falling short of Q3 earnings and revenue estimates and reporting a 10.6% year-over-year revenue decrease, the company recently increased its quarterly dividend to $0.84 per share. Institutional investors have notably adjusted their stakes in EMN, with significant increases in holdings by several firms during the third quarter.

**4. Eastman Chemical Co Is Quietly Going Viral With Wall Street â€“ But Should You Even Care?**
- Source: AD HOC NEWS | 20260103T011408 | Somewhat-Bullish | Relevance: 100%
- Eastman Chemical Co is gaining quiet attention on Wall Street and financial social media, prompting the question of its investment merit. While not a "moonshot" stock, EMN is presented as a value play with a stable business model tied to real-world demand, paying dividends, and focusing on incremental improvements in specialty materials. The article suggests it's a suitable option for long-term, value-oriented investors seeking consistency rather than high-volatility, viral trends.

**5. NewMarket Corporation's (NYSE:NEU) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?**
- Source: Simply Wall Street | 20260104T150931 | Neutral | Relevance: 63%
- NewMarket Corporation's stock has dropped 20% in the last three months, but its fundamentals suggest a closer look is warranted. The company boasts a strong Return on Equity (ROE) of 27%, significantly higher than its industry average, and has demonstrated consistent net income growth. This strength, coupled with a high reinvestment rate of retained profits, indicates promising long-term potential despite recent stock performance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Wells Fargo | $70 | $70 | 0% |
| 2025-12-18 | Citigroup | $72 | $70 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Wells Fargo | down | Equal-Weight |
| 2025-12-18 | Citigroup | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.6% (-2.2%)
- Blackrock Inc.: 7.0% (+0.9%)
- State Street Corpora: 5.0% (+24.3%)
- Capital Research Glo: 3.7% (-1.0%)
- Dimensional Fund Adv: 3.5% (+14.4%)

### Key Risks

1. Valuation risk: PEG 3.8x with declining EPS estimates leaves no margin for error.
2. Long-term trend broken: trading 8.3% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.79 signals overvaluation risk, limited margin of safety. Forward P/E 10.5x attractive for 13% earnings growth. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $7.4B |
| Beta | 1.24 |
| 52W Range | $56.11 - $103.82 |
| Short Interest | 5.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.79 |
| Forward P/E | 10.5 |
| Current P/E | 11.9 |
| YoY Growth | 13.4% |
| EPS Direction | FALLING |

### Technicals

MRS_20 improving modestly (+0.7% over 5 days). Below STRENGTH zone by 1.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 59. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.12% (CS: 64) | Neutral |
| RSI_14 | 59.1 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.049x | Above |
| vs SMA200 | 0.917x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $64.77
- **Stop Loss:** $61.79 (4.6% risk)
- **Target:** $67.75 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 463
- **Position Value:** $29,988.51
- **Portfolio %:** 29.99%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-01-29 (Est: $0.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.14 | -2.2% |
| 2025Q2 | $1.75 | $1.60 | -8.7% |
| 2025Q1 | $1.89 | $1.91 | +1.2% |
| 2024Q4 | $1.57 | $1.87 | +18.9% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*